优宁维 reported revenue of ¥0.57B for the period ended 2026-06-30, +12.6% year on year. Net income was ¥-0.01B, a -2.1% net margin on a 20.6% gross margin. The largest revenue line is 生命科学试剂 at 78% of the total. Free cash flow for the period was ¥-0.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.57B | +12.6% |
| Gross profit | ¥0.12B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.01B | — |
| Gross margin | 20.6% | Net margin -2.1% |
| Revenue Q/Q | +19.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 生命科学试剂 | ¥0.44B | 78.0% |
| 生命科学仪器及耗材 | ¥0.10B | 17.5% |
| 综合技术服务 | ¥0.03B | 4.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.45B | 79.4% |
| R&D | ¥0.04B | 6.8% |
| SG&A | ¥0.10B | 17.0% |
| Tax & other | ¥-0.01B | -1.9% |
| Item | Amount |
|---|---|
| Total assets | ¥2.25B |
| Total liabilities | ¥0.32B |
| Shareholders' equity | ¥1.93B |
| Equity / assets | 85.9% |
| Operating cash flow | ¥-0.04B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.06B |
| Cash conversion (OCF / net income) | 1378% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
建研设计 ・ 通灵股份 ・ 零点有数 ・ 锡南科技 ・ 易点天下 ・ 君逸数码 ・ 毓恬冠佳 ・ 中科环保 ・ 逸豪新材 ・ 迪阿股份 ・ 天亿马 ・ 泽宇智能
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies